bromoacetamido peg2 c2 acid

Bromoacetamido-PEG2-C2-acid is a polyethylene glycol (PEG)-based linker utilized in PROTAC synthesis[1].

dMCL1-2 is a potent and selective myeloid leukemia 1 (MCL1) degrading agent based on PROTAC, binding to MCL1 with a KD of 30 nM and activating the apoptosis mechanism by degrading MCL1.

1,2-Bis(2-iodoethoxy)ethane is a PEG-based PROTAC linker used in the synthesis of MT802 and SJF620, which are potent PROTAC BTK degraders with DC50s of 1 nM and 7.9 nM, respectively [1].

5-Ethynyl-2'-deoxyuridine (EdU) is a nucleoside analog of thymidine used to monitor de novo DNA synthesis through click chemistry and serves as an alkyl chain-based PROTAC linker for synthesizing PROTACs.

Pomalidomide-C2-acid is a PROTAC building block.

2-Phthalimidehydroxy-acetic acid is an alkyl chain-based PROTAC linker utilized in PROTAC synthesis.

Cbz-NH-PEG12-C2-acid is a PEG-based linker for PROTACs, facilitating the connection of two essential ligands to form PROTAC molecules, thereby enabling selective protein degradation by leveraging the ubiquitin-proteasome system within cells.

PROTAC ERRα ligand 2 is an inverse agonist for the estrogen-related receptor α (ERRα) with an IC50 of 5.67 nM.

Thalidomide-O-amido-PEG-C2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate, incorporating a Thalidomide-based cereblon ligand and a linker. This compound is used in the synthesis of PROTACs.

TSPO ligand-2 (Carbonic acid) is a ligand of AUTAC1 which contains a p-fluorobenzylguanine and a Fumagillol moiety.

Mal-PEG2-C2-Boc (Mal-PEG2-T-Butyl Ester) is a PEG-based PROTAC linker. Mal-PEG2-C2-Boc can be used in the synthesis of PROTACs.

Thalidomide-O-amido-PEG2-C2-NH2 hydrochloride, incorporating an E3 ligase ligand and a linker, can be used as an immunomodulator for the treatment of cancer.

Hydroxy-PEG4-(CH2)2-Boc is an uncleavable ADC linker utilized in the synthesis of antibody-drug conjugates (ADCs) and can also be employed in the synthesis of PROTAC.

Mal-amido-PEG2-C2-amido-Ph-C2-CO-AZD (PF-05231023) is a long-acting fibroblast growth factor 21 (FGF21) analog and FGF21-receptor agonist, suitable for development as a potential treatment for T2DM.

Thalidomide-O-amido-PEG2-C2-NH2 TFA (E3 Ligase Ligand-Linker Conjugates 24 TFA) is a synthesized E3 ligase ligand-linker conjugate incorporating the Thalidomide-based cereblon ligand and a 2-unit PEG linker, utilized in PROTAC technology.

Bromo-PEG3-C2-acid, a PEG-based PROTAC linker, can be utilized in PROTAC synthesis[1].

PROTAC Bcl-xL degrader-2, based on von Hippel-Lindau ligand, is a potent degrader of Bcl-xL (a Bcl-2 family member), demonstrating an IC 50 of 0.6 nM.

PROTAC EGFR degrader 2 is a potent compound with an IC50 of 4.0 nM, demonstrating strong antiproliferative activity, and a DC50 of 36.51 nM, indicating robust EGFR degradation activity. It is suitable for synthesizing nitroreductase (NTR)-responsive PROTACs [1].

(R)-Azetidine-2-carboxylic acid, with catalog number T66331 and CAS number 7729-30-8, is a valuable organic compound for life sciences research.

Thalidomide-O-amido-PEG2-C2-NH2, which combines an E3 ligase ligand with a linker, serves as an immunomodulator for cancer treatment.

Thiol-PEG2-acid is a PEG derivative containing a thiol group and a terminal carboxylic acid. The hydrophilic PEG spacer increases solubility in aqueous media. The thiol group reacts with maleimide, OPSS, vinylsulfone and transition metal surfaces including gold, silver, etc. The terminal carboxylic acid can be reacted with primary amine groups in the presence of activators (e.g. EDC, or DCC) to form a stable amide bond.

Br-PEG6-C2-acid, a PEG-based linker for PROTACs, connects two essential ligands, facilitating the formation of PROTAC molecules and enabling selective protein degradation via the ubiquitin-proteasome system within cells.

N-(Azido-PEG2)-N-Boc-PEG4-acid is a polyethylene glycol (PEG)-based linker developed for synthesizing PROteolysis TArgeting Chimeras (PROTACs)[1].

S-Acetyl-PEG3-C2-acid is a PEG-based linker for PROTACs that joins two essential ligands, facilitating selective protein degradation via the ubiquitin-proteasome system within cells.

N-Mal-N-bis(PEG2-acid) is a PEG-based linker used in PROTACs to join two essential ligands, facilitating selective protein degradation through the ubiquitin-proteasome system in cells.

endo-BCN-PEG2-C2-NHS ester is a PEG-based linker for PROTACs that connects two critical ligands, essential for the formation of PROTAC molecules, enabling selective protein degradation via the ubiquitin-proteasome system within cells.

Bis-Tos-(2-hydroxyethyl disulfide) is a cleavable linker used in the synthesis of antibody-drug conjugates (ADCs) [1].

DBCO-(PEG2-Val-Cit-PAB)2 is a dual-cleavable linker used in antibody-drug conjugates (ADCs).

N-Mal-N-bis(PEG2-C2-Boc) is a polyethylene glycol (PEG)-based linker used in proteolysis targeting chimeras (PROTACs)[1].

Propargyl-O-C1-amido-PEG2-C2-NHS ester is a non-cleavable 2-unit PEG linker used in antibody-drug conjugation (ADC) to connect antibodies with drugs.

NH-bis(PEG2-C2-Boc) is an alkyl ether-based linker used in the synthesis of PROTACs [1].

Pomalidomide-amido-C4-amido-PEG2-C2-NH-Boc is a novel synthesized conjugate compound functioning as an E3 ligase ligand-linker in PROTAC technology. Incorporating a Pomalidomide-derived cereblon ligand that selectively binds to the E3 ligase cereblon and a 2-unit PEG linker, it provides stability and flexibility to the conjugate.

Mal-amido-PEG8-C2-acid (US2018339985, example 142) is a noncleavable linker for antibody-drug conjugates (ADCs) [1].

6-O-2-Propyn-1-yl-D-galactose functions as an irreversible glycolinker, facilitating the attachment of cytotoxic drugs for applications in antibody-drug conjugation (ADC).

PROTAC BET-binding moiety 2 is an inhibitor of the BET bromodomain.

PROTAC ERRα Degrader-2 is a compound consisting of an MDM2 ligand binding group, a linker, and an estrogen-related receptor alpha (ERRα) binding group. This compound is designed to specifically degrade estrogen-related receptor alpha (ERRα), acting as an ERRα degrader[1].

Fmoc-PEG2-CH2CH2-NHS ester is a polyethylene glycol (PEG)-based linker constructed for the synthesis of proteolysis targeting chimeras (PROTACs).

C2-Bis-phosphoramidic acid diethyl ester is an alkyl chain-derived PROTAC linker used in the synthesis of PROTACs [1].

Fmoc-NMe-PEG4-C2-acid, a PEG-based linker for PROTACs, connects two essential ligands crucial for PROTAC molecule formation and facilitates selective protein degradation by leveraging the ubiquitin-proteasome system within cells.

4-Methyl-4-(pyridin-2-yldisulfanyl)pentanoic acid is a cleavable linker compound used in the synthesis of antibody-drug conjugates (ADCs) [1].

RIPK2-IN-2 (example 25) is a RIP2 kinase PROTAC inhibitor that effectively blocks RIP2-dependent pro-inflammatory signaling and regulates RIP2 kinase activity in autoinflammatory diseases [1].

PROTAC VEGFR-2 degrader-2 (PROTAC-4), a specific degrader of VEGFR-2, demonstrates minimal inhibition of VEGFR-2 (IC50 > 1 μM) and low anti-proliferative activity towards EA.hy926 cells (IC50 > 100 μM) [1].

PROTAC VEGFR-2 Degrader-1 (PROTAC-1), a specific degrader of PROTAC VEGFR-2, demonstrates minimal inhibition of VEGFR-2 (IC50 > 1 μM) and exhibits low anti-proliferative effects on EA.hy926 cells (IC50 > 100 μM) [1].

PROTAC BRD4 Ligand-2 Hydrochloride serves as a ligand targeting the BRD4 protein, specifically designed for use with PROTAC CFT-2718.

Thalidomide-O-amido-PEG1-(C1-PEG)2-C2-NH2 is a synthesized E3 ligase ligand-linker, incorporating a cereblon ligand based on Thalidomide and a 3-unit PEG linker, specifically designed for PROTAC technology applications.

SNIPER(TACC3)-2 targets TACC3 protein degradation via the ubiquitin-proteasome pathway. It induces cancer cell death.

PROTAC STAT3 degrader-2 is a selective and effective PROTAC degrader of the STAT3 protein, exhibiting a DC50 of 3.54 μM in Molm-16 cells. It holds potential for cancer research [1].

Acid-PEG2-C2-Boc is a PEG-based linker for PROTACs, joining two essential ligands crucial for forming PROTAC molecules, enabling selective protein degradation through the ubiquitin-proteasome system within cells.